Browse by Poster Presenter

Skip to main content

ACoP 2024 Main banner

Conference Program

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

L
Lachi Silva, Larissa

Novartis Pharmaceuticals Corporation
(W-068) Dose determination of Lutathera in adolescents via popPK and dosimetry modeling and simulation
Larissa Lachi Silva
Favorite
Laffont, Celine

Indivior Inc
(M-092) Integrated Quantitative Systems Pharmacology and Pharmacometric Model to Evaluate Effective Buprenorphine Induction Treatment Strategies in the Era of Synthetic Opioids
Celine Laffont
Favorite
Lanke, Shankar

Astrazeneca
(M-062) Successful Dose Optimization and Recommended Phase III Dose Determination of Saruparib (PARP1 Selective Inhibitor) Through MIDD and Comprehensive Quantitative Clinical Pharmacology
Shankar Lanke
Favorite
León, Cristhyne

Novadiscovery
(W-071) Mathematical modeling can help to successfully translate preclinical findings in mice models of asthma into first-in-human trials
Cristhyne León
Favorite
Lee, Dongjin

Amgen
(T-075) Enhancing Parameter Estimation Process for Pharmacokinetic-Pharmacodynamic Models with Meta-heuristic Optimization Approaches
Dongjin Lee
Favorite
Lee, Heekyung

University of Maryland School of Pharmacy
(T-076) Population Pharmacokinetic-Pharmacodynamic Modeling for Triapine to Optimize Dosing Regimen
Heekyung Lee
Favorite
Lee, Jaeyeon

Yuhan Corporation
(M-063) Population Pharmacokinetic/Pharmacodynamic Analysis of YH35995 for the First-in-Human Dose Prediction
Jaeyeon Lee
Favorite
Lee, Sooyoung

University of Maryland School of Pharmacy
(W-069) Exploring Appropriate Prior Distributions for Covariance Matrix Estimation in Bayesian Population Pharmacokinetic Analysis
Sooyoung Lee
Favorite
Leonov, Vladislav

InSysBio UK Ltd
(W-072) Unraveling Major Inflammatory Cytokines Serum Distribution Patterns in Systemic Lupus Erythematosus Patients: Insights from the CYTOCON Database
Vladislav Leonov
Favorite
Liao, Laura

Merck & Co., Inc
(M-065) Decoding Mean Viral Load in RSV Human Challenge Studies
Laura Liao
Favorite
Liao, Xiaozhi

UNC-Chapel Hill
(M-066) Optimizing Clinical Translation of Bispecific T Cell Engagers through Context Unification with a Quantitative Systems Pharmacology Model
Xiaozhi Liao
Favorite
Lien, Yi Ting (Kayla)

Genentech Inc
(W-074) Exposure-response analyses of GO39932: a Phase Ia/b study of giredestrant in estrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Yi Ting (Kayla) Lien
Favorite
Lim, Chay Ngee

Pfizer Inc., Cambridge, MA, USA
(W-075) Population pharmacokinetic modeling to support dose selection of rimegepant in pediatrics
Chay Ngee Lim
Favorite
Lindauer, Andreas

Calvagone SAS
(W-076) Interactive Pharmacometric Simulations and Model Exploration with e-Campsis
Andreas Lindauer
Favorite
(W-077) An Introduction to Campsis: The R-Based Open-Source PK/PD Simulation Suite
Andreas Lindauer
Favorite
Link, Kathryn

Pharmacometrics & Systems Pharmacology, Translational Clinical Sciences, Pfizer Inc
(T-079) A mechanistic QSP model of CRS allows for quantitative assessment of dose priming of CD3 bispecific antibody (BsAb) therapeutics.
Kathryn Link
Favorite
Li, Peizhi

the University of Iowa College of Pharmacy
(M-064) A semi-mechanistic pharmacometrics model to quantitatively characterize delta-9-tetrahydrocannabinol (THC) and its metabolites’ disposition among oral cannabis users
Peizhi Li
Favorite
Liu, Alan

Pfizer
(M-067) Stochastic Simulation and Estimation (SSE) for Design of Sample Size and Time Points in Pediatric Studies
Alan Liu
Favorite
Liu, Huan

Drug Clinical Trial Center, Peking University Third Hospital, Beijing 100191, china
(T-080) A phase I open-label sequential clinical trial and population oral minimal model to study pharmacodynamic interactions of dorzagliatin and empagliflozin in patients with type 2 diabetes and obesity
Huan Liu
Favorite
Li, Xiaobin

GSK
(W-073) xplorer: a Flexible Shiny App for Data Visualization, Exploration and Quality Assurance
Xiaobin Li
Favorite
Li, Yisheng

University of Texas MD Anderson Cancer Center
(T-078) A Bayesian Semi-Mechanistic Dose-Finding Design for Phase I Drug Combination Trials in Oncology
Yisheng Li
Favorite
Li, Yuezhe

Metrum Research Group
(T-077) Quantitative Systems Pharmacology Modeling of Loncastuximab Tesirine Combined with Mosunetuzumab and Glofitamab Helps Guide Dosing for Patients with DLBCL
Yuezhe Li
Favorite
Long, Yuhan

University of Minnesota
(W-078) Effect of Convenience Sampling on Overall Drug Exposure during Pregnancy
Yuhan Long
Favorite
Lu, Dan

Genentech
(M-068) A translational QSP model to characterize the preclinical pharmacodynamics of combining a KRAS G12C inhibitor with a SHP2 inhibitor
Dan Lu
Favorite
Lumen, Annie

Clinical Pharmacology Modeling & Simulation, Amgen
(T-082) Optimizing Clinical Dosing Strategies to Mitigate Corneal Toxicity: Ocular PBPK Model-Based Evaluation of the Extent and Rate of Therapeutic Protein Distribution in the Human Cornea
Annie Lumen
Favorite
Luo, Dandan

Janssen Research & Development, LLC
(W-142) Population Pharmacokinetics and Exposure-response Analyses of Lazertinib in Combination with Amivantamab as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic NSCLC
Dandan Luo
Favorite
Lu, Yasong

Bicycle Therapeutics
(T-081) Application of Model Informed Drug Development (MIDD) to BT8009, a Bicycle Toxin Conjugate (BTC®), in Patients with Advanced Urothelial Cancer
Yasong Lu
Favorite
Lyu, Xintian

University of Minnesota
(W-079) Characterizing Pharmacokinetics Effects on Measures of Overall Drug Exposure during Pregnancy
Xintian Lyu
Favorite